(MENAFN- EIN Presswire) EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

Tumor Necrosis Factor Inhibitor Drugs Market Growth Forecast: What To Expect By 2025?
The market size of tumor necrosis factor inhibitor drugs has seen a slight increase in the past few years. It is projected to rise from $42.22 billion in 2024 to $42.47 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 0.6%. This growth in the historical period can be traced back to factors like clinical efficacy, FDA approvals, a rise in disease incidence, clinical research and trials, adoption and endorsement by physicians, and patient demand and satisfaction.

In the upcoming years, the tumor necrosis factor inhibitor drugs market is predicted to experience consistent growth. It's anticipated that the market will expand to ""$47.15 billion by 2029, with a compound annual growth rate (CAGR) of 2.6%. The projected growth within this period can be credited to factors such as the progression of emerging markets, modifications and approvals in regulations, the application of personalized medicine methodologies, enhancement in healthcare awareness and accessibility, and the advancement of biological therapies. Key trends during the forecasted period are patient-focused solutions, concrete evidence and data, emphasis on safety and side effects, innovative drug delivery systems, and broadened clinical applications.

Download a free sample of the tumor necrosis factor inhibitor drugs market report:

What Are Key Factors Driving The Demand In The Global Tumor Necrosis Factor Inhibitor Drugs Market?
The rise in the occurrence of autoimmune diseases is forecasted to fuel the tumor necrosis factor inhibitor drugs market's expansion. Autoimmune diseases occur when the body's immune system mistakenly attacks and destroys healthy tissue. Tumor necrosis factor inhibitor drugs are utilized in the treatment of autoimmune diseases to halt inflammation, which can cause pain, swelling, or illness. These medications work by blocking the action that leads to inflammation, thereby enhancing the immune system's stability and protecting the body against further inflammation. For instance, the Autoimmune Association, a US-based non-profit organization devoted to raising awareness about autoimmune diseases, reported in June 2022 that 4.7 million American men had autoimmune diseases, account for 20% of all autoimmune disease patients. 31 million Americans are afflicted with 80-150 distinct autoimmune diseases in 2022, a figure that is expected to rise in the future. As a result, the escalating prevalence of autoimmune diseases is spurring the growth of the tumor necrosis factor inhibitor drugs market.

Who Are The Leading Players In The Tumor Necrosis Factor Inhibitor Drugs Market?
Major players in the Tumor Necrosis Factor Inhibitor Drugs include:

. AbbVie Inc.
. Amgen Inc.
. Johnson & Johnson Services Inc.
. UCB S.A.
. Novartis International AG
. Pfizer Inc.
. Samsung Bioepis Co. Ltd.
. Sanofi SA
. Merck & Co. Inc.
. Boehringer Ingelheim Pharmaceuticals

What Are Some Emerging Trends In The Tumor Necrosis Factor Inhibitor Drugs Market?
One significant trend in the tumor necrosis factor inhibitor drugs market is the emphasis on product innovation. Major players in this market are dedicating resources to create innovative drugs to solidify their market presence. For example, in May 2024, Teva Pharmaceuticals, a company based in the US, collaborated with a biotechnology firm from Luxembourg known as Alvotech. They announced that an injection named SIMLANDI (adalimumab-ryvk) will be available in the U.S as an interchangeable biosimilar to Humira. This drug is designed to treat various conditions such as adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, and adult uveitis.

Analysis Of Major Segments Driving The Tumor Necrosis Factor Inhibitor Drugs Market Growth
The tumor necrosis factor inhibitor drugs market covered in this report is segmented –
1) By Product Type: Humira, Enbrel, Remicade, Simponi Or Simponi Aria, Cimzia, Biosimilars
2) By Route Of Administration: Subcutaneous Injection, Intravenous Injection
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Other Applications

Subsegments:
1) By Humira: Humira (adalimumab)
2) By Enbrel: Enbrel (etanercept)
3) By Remicade: Remicade (infliximab)
4) By Simponi Or Simponi Aria: Simponi (golimumab), Simponi Aria
5) By Cimzia: Cimzia (certolizumab pegol)
6) By Biosimilars: Biosimilars Of Humira, Biosimilars Of Enbrel, Biosimilars Of Remicade, Biosimilars Of Simponi, Biosimilars Of Cimzia

View the full tumor necrosis factor inhibitor drugs market report:

Which Region Is Expected To Lead The Tumor Necrosis Factor Inhibitor Drugs Market By 2025?
In 2024, the Tumor Necrosis Factor Inhibitor Drugs market was dominated by North America. However, the highest growth rate is predicted to come from the Asia-Pacific region during the forecast period. The report includes an analysis of various regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Tumor Necrosis Factor Inhibitor Drugs Market 2025, By The Business Research Company

Drug Delivery Devices Global Market Report 2025
/report/drug-delivery-devices-global-market-report

Drugs For Immunotherapy Global Market Report 2025
/report/drugs-for-immunotherapy-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2025
/report/drugs-for-hormonal-replacement-therapy-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...
The Business Research Company -

Follow Us On:
. LinkedIn: "

MENAFN23112025003118003196ID1110386199